UBS Group’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1M | Buy |
99,006
+19,468
| +24% | +$198K | ﹤0.01% | 4356 |
|
|
2025
Q1 | $444K | Buy |
79,538
+4,609
| +6% | +$25.7K | ﹤0.01% | 4762 |
|
|
2024
Q4 | $605K | Buy |
74,929
+3,374
| +5% | +$27.2K | ﹤0.01% | 4572 |
|
|
2024
Q3 | $733K | Sell |
71,555
-9,252
| -11% | -$94.8K | ﹤0.01% | 3822 |
|
|
2024
Q2 | $571K | Sell |
80,807
-13,254
| -14% | -$93.7K | ﹤0.01% | 3841 |
|
|
2024
Q1 | $1.29M | Buy |
94,061
+53,088
| +130% | +$730K | ﹤0.01% | 3360 |
|
|
2023
Q4 | $377K | Buy |
40,973
+23,701
| +137% | +$218K | ﹤0.01% | 4174 |
|
|
2023
Q3 | $104K | Sell |
17,272
-4,996
| -22% | -$30.2K | ﹤0.01% | 4696 |
|
|
2023
Q2 | $173K | Buy |
+22,268
| New | +$173K | ﹤0.01% | 4550 |
|
|
2023
Q1 | – | Sell |
-4,433
| Closed | -$26.1K | – | 8866 |
|
|
2022
Q4 | $26.1K | Buy |
4,433
+4,300
| +3,233% | +$25.3K | ﹤0.01% | 6209 |
|
|
2022
Q3 | $0 | Sell |
133
-2,071
| -94% | – | ﹤0.01% | 9552 |
|
|
2022
Q2 | $10K | Buy |
+2,204
| New | +$10K | ﹤0.01% | 6944 |
|
|
2022
Q1 | – | Sell |
-62,399
| Closed | -$917K | – | 9475 |
|
|
2021
Q4 | $917K | Buy |
62,399
+36,413
| +140% | +$535K | ﹤0.01% | 3511 |
|
|
2021
Q3 | $544K | Buy |
25,986
+18,747
| +259% | +$392K | ﹤0.01% | 3679 |
|
|
2021
Q2 | $128K | Sell |
7,239
-24,265
| -77% | -$429K | ﹤0.01% | 4665 |
|
|
2021
Q1 | $772K | Buy |
31,504
+29,977
| +1,963% | +$735K | ﹤0.01% | 3589 |
|
|
2020
Q4 | $52K | Sell |
1,527
-83
| -5% | -$2.83K | ﹤0.01% | 5152 |
|
|
2020
Q3 | $40K | Sell |
1,610
-1,234
| -43% | -$30.7K | ﹤0.01% | 4947 |
|
|
2020
Q2 | $96K | Buy |
+2,844
| New | +$96K | ﹤0.01% | 4523 |
|